Wang Chang, Wang Siyu, Kang Diana D, Dong Yizhou
Department of Oncological Sciences, Icahn Genomics Institute, Precision Immunology Institute, Tisch Cancer Institute, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
BMEmat. 2023 Sep;1(3). doi: 10.1002/bmm2.12039. Epub 2023 Jul 19.
Cell therapy has revolutionized the treatment of various diseases, such as cancers, genetic disorders, and autoimmune diseases. Currently, most cell therapy products rely on ex vivo cell engineering, which requires sophisticated manufacturing processes and poses safety concerns. The implementation of in situ cell therapy holds the potential to overcome the current limitations of cell therapy and provides a broad range of applications and clinical feasibility in the future. A variety of biomaterials have been developed to improve the function and target delivery to specific cell types due to their excellent biocompatibility, tunable properties, and other functionalities, which provide a reliable method to achieve in vivo modulation of cell reprogramming. In this article, we summarize recent advances in biomaterials for in situ cell therapy including T cells, macrophages, dendritic cells, and stem cells reprogramming leveraging lipid nanoparticles, polymers, inorganic materials, and other biomaterials. Finally, we discuss the current challenges and future perspectives of biomaterials for in situ cell therapy.
细胞疗法已经彻底改变了各种疾病的治疗方式，如癌症、遗传疾病和自身免疫性疾病。目前，大多数细胞治疗产品依赖于体外细胞工程，这需要复杂的制造工艺并带来安全问题。原位细胞疗法的实施有可能克服细胞疗法当前的局限性，并在未来提供广泛的应用和临床可行性。由于其优异的生物相容性、可调特性和其他功能，已经开发出多种生物材料来改善功能并将其靶向递送至特定细胞类型，这为实现体内细胞重编程调节提供了一种可靠的方法。在本文中，我们总结了用于原位细胞疗法的生物材料的最新进展，包括利用脂质纳米颗粒、聚合物、无机材料和其他生物材料对T细胞、巨噬细胞、树突状细胞和干细胞进行重编程。最后，我们讨论了用于原位细胞疗法的生物材料当前面临的挑战和未来前景。
